Aldeyra Therapeutics, Inc. (ALDX) Shares Bought by Sphera Funds Management LTD.
Sphera Funds Management LTD. increased its position in Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) by 31.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 875,931 shares of the biotechnology company’s stock after buying an additional 207,431 shares during the period. Sphera Funds Management LTD. owned about 14.03% of Aldeyra Therapeutics worth $4,117,000 at the end of the most recent quarter.
Other hedge funds also recently bought and sold shares of the company. Renaissance Technologies LLC bought a new stake in Aldeyra Therapeutics during the first quarter worth about $132,000. Sabby Management LLC bought a new stake in Aldeyra Therapeutics during the first quarter worth about $898,000. Perceptive Advisors LLC increased its stake in Aldeyra Therapeutics by 48.7% in the first quarter. Perceptive Advisors LLC now owns 2,885,458 shares of the biotechnology company’s stock worth $12,897,000 after buying an additional 945,000 shares in the last quarter. Finally, Hikari Power Ltd increased its stake in Aldeyra Therapeutics by 186.4% in the second quarter. Hikari Power Ltd now owns 107,858 shares of the biotechnology company’s stock worth $507,000 after buying an additional 70,196 shares in the last quarter. 49.09% of the stock is owned by institutional investors.
Shares of Aldeyra Therapeutics, Inc. (ALDX) traded up 3.61% during trading on Friday, reaching $4.30. 21,340 shares of the company were exchanged. The stock’s 50 day moving average is $4.48 and its 200 day moving average is $4.69. The company’s market capitalization is $26.85 million. Aldeyra Therapeutics, Inc. has a 1-year low of $3.80 and a 1-year high of $8.19.
Aldeyra Therapeutics (NASDAQ:ALDX) last announced its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.35) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.02. Equities analysts anticipate that Aldeyra Therapeutics, Inc. will post ($1.63) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Aldeyra Therapeutics, Inc. (ALDX) Shares Bought by Sphera Funds Management LTD.” was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another site, it was stolen and reposted in violation of United States and international trademark and copyright law. The legal version of this report can be viewed at https://www.watchlistnews.com/aldeyra-therapeutics-inc-aldx-shares-bought-by-sphera-funds-management-ltd/1538187.html.
ALDX has been the subject of a number of research analyst reports. Zacks Investment Research downgraded shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, May 30th. Stifel Nicolaus reaffirmed a “buy” rating and set a $16.00 price objective on shares of Aldeyra Therapeutics in a report on Wednesday, May 31st. HC Wainwright set a $18.00 price objective on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Thursday, June 15th. Finally, Canaccord Genuity set a $12.00 price objective on shares of Aldeyra Therapeutics and gave the stock a “buy” rating in a report on Wednesday, June 14th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Aldeyra Therapeutics has an average rating of “Buy” and a consensus target price of $14.15.
In other news, major shareholder Life Sciences Maste Perceptive bought 296,007 shares of Aldeyra Therapeutics stock in a transaction dated Friday, June 30th. The shares were acquired at an average price of $4.60 per share, with a total value of $1,361,632.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 28.40% of the company’s stock.
About Aldeyra Therapeutics
Aldeyra Therapeutics, Inc, formerly Aldexa Therapeutics, Inc, is a biotechnology company. The Company’s principal activities include raising capital and research and development activities. The Company’s segment is the identification and development of a treatment for diseases related to high levels of aldehydes.
Receive News & Ratings for Aldeyra Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.